What is Replimune Group's change in AP?

Replimune Group (REPL) reported change in AP of -$730K in Q4 2025.

What does change in AP mean?

Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.

Replimune Group REPL Change in AP

Change in AP at other companies

AmgenAMGN

$571M+14.9%

Regeneron PharmaceuticalsREGN

$107.7M+150%

Inhibrx Biosciences, Inc.INBX

$2.82M+898%

ImmunomeIMNM

$1.42M+137%

CG OncologyCGON

$2.52M+1,079%

Erasca, Inc.ERAS

$1.18M-34.1%

Other financials

Income statement

See full

Operating income-$71.9M-8.9%

Net income-$70.9M-6.9%

EPS (diluted)-$0.77+2.5%

Balance sheet

See full

Cash & equivalents$124.7M-28.3%

Total debt$79.2M+0.5%

Total equity$210.5M-56.4%

Total assets$333.6M-44.7%

Cash flow

See full

Operating cash flow-$66.0M-30.1%

CapEx$135.0K-92.5%

Free cash flow-$66.1M-25.9%

Valuation

See full

Market cap$930.59M+28.6%

Enterprise value$885.15M+28.3%

Returns & leverage

See full

Return on equity-90.9%+362pp

Debt / equity0.4×+0.2×

Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Replimune Group's change in AP?: Replimune Group (REPL) reported change in AP of -$730K in Q4 2025.
What does change in AP mean?: Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.